Age: 76.0
Sex: F
Vaccine: VARZOS
Symptoms: Neuropathy peripheral, Osteopenia, PO2 normal, Pulmonary mass, Rash
Clinical narrative: This spontaneous report as received from a currently 83 year old female consumer with no allergies or drug sensitivities, via her medical records, refers to herself. The patient's medical history included chickenpox. On 01-OCT-2007, the patient was vaccinated with ZOSTAVAX, 0.65 ml, subcutaneously (lot number not available, expiration date reported as 05-OCT-2008). No co-suspect or concomitant therapies were provided. On 23-SEP-2013, at the age of 82 years, the patient was diagnosed with an unspecified peripheral neuropathy. On 21-OCT-2013, the patient was diagnosed with acquired hypothyroidism, and on 15-JAN-2014, she was diagnosed with hypothyroidism. On 12-FEB-2014, the patient was diagnosed with pulmonary nodule. On 07-JAN-2015, the patient was diagnosed with hypertension and osteopenia. Approximately on 11-FEB-2015 (also reported as approximately on 03-MAR-2015; approximately 2 weeks before the visit), the patient experienced shingles on the right area of  her face, near the eye. On 04-MAR-2015, the patient visited an urgent care clinic and was diagnosed with herpes zoster without complication and rash (other nonspecific skin eruption). She was prescribed valacyclovir 1 g tablet (1 tablet by mouth twice a day for 7 days), prednisone 20 mg tablet (1 tablet by mouth twice a day), tobramycin 0.3% (1 application in right eye three times a day), and was recommended to try calamine lotion. Tobramycin was not used as the shingles did not progress into the eye. The patient was recommended to consult with an ophthalmologist urgently, and call or return to the clinic if the condition worsened. On 17-MAR-2015, the patient was seen in health center. It was reported that the patient saw her ophthalmologist twice since the initial diagnosis of herpes zoster. The history of present illness included shingles; the rash was located primarily on the face and was described as painful, red, and spread over a wide area, and associated symptoms included blurred vision (start date of blurred vision was not specified). On this day, vital signs included height (Ht) 5 ft, 1 in, weight (Wt) 108 lbs (estimated), body mass index (BMI) 20.6, blood pressure (BP) 134/74 mm Hg (right arm, sitting), pulse (P) 80 bpm (finger clip, sitting), serum creatinine (scr) 0.78 mg/dl, glomerular filtration rate (GFR) 46.34 and oxygen saturation (O2 Sat) 95% (room air). On the same day, the patient was diagnosed with shingles. The medication list on this visit included amlodipine 5 mg tablet (1 orally, every day), amitriptyline Hcl 10 mg tablet (1 orally hora Somme (hs)), and aspirin (ASA) 81 mg chewable tablet (1 orally, every day, started on 23-SEP-2013). Since the patient had no pain in this date, there was no new order for medications, she was kept on treatment with valacyclovir and prednisone, and was recommended to call the nurse at any time as needed. As of 24-APR-2015, the consumer was wondering if she should get another shingle shot. At the time of the report, the outcome of herpes zoster, neuropathy peripheral, hypothyroidism, pulmonary mass, osteopenia, hypertension and vision blurred was unknown. The causality between ZOSTAVAX and the reported events was not provided. All available medical records will be provided upon request. Additional information has been requested.